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Abstract
Background: The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several
clinical trials and is now being tested in combination with immune checkpoint blockade. Combination
therapies offer the best chance of disease control; however, the design of successful combination strategies
requires a deeper understanding of the mechanisms underpinning CVA21 efficacy, in particular, the role of
CVA21 anti-tumor immunity. Therefore, this study aimed to examine the ability of CVA21 to induce human
anti-tumor immunity, and identify the cellular mechanism responsible.
Methods: This study utilized peripheral blood mononuclear cells from i) healthy donors, ii) Acute Myeloid
Leukemia (AML) patients, and iii) patients taking part in the STORM clinical trial, who received intravenous
CVA21; patients receiving intravenous CVA21 were consented separately in accordance with local institutional
ethics review and approval. Collectively, these blood samples were used to characterize the development of
innate and adaptive anti-tumor immune responses following CVA21 treatment.
Results: An Initial characterization of peripheral blood mononuclear cells, collected from cancer patients
following intravenous infusion of CVA21, confirmed that CVA21 activated immune effector cells in patients.
Next, using hematological disease models which were sensitive (Multiple Myeloma; MM) or resistant (AML) to
CVA21-direct oncolysis, we demonstrated that CVA21 stimulated potent anti-tumor immune responses,
including: 1) cytokine-mediated bystander killing; 2) enhanced natural killer cell-mediated cellular cytotoxicity;
and 3) priming of tumor-specific cytotoxic T lymphocytes, with specificity towards known tumor-associated
antigens. Importantly, immune-mediated killing of both MM and AML, despite AML cells being resistant to
CVA21-direct oncolysis, was observed. Upon further examination of the cellular mechanisms responsible for
CVA21-induced anti-tumor immunity we have identified the importance of type I IFN for NK cell activation,
and demonstrated that both ICAM-1 and plasmacytoid dendritic cells were key mediators of this response.
Conclusion: This work supports the development of CVA21 as an immunotherapeutic agent for the treatment
of both AML and MM. Additionally, the data presented provides an important insight into the mechanisms of
CVA21-mediated immunotherapy to aid the development of clinical biomarkers to predict response and
rationalize future drug combinations.
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Background
Oncolytic virotherapy (OVT) has made significant progress
for the treatment of solid malignancies over recent years,
not least following the FDA approval of a genetically engi-
neered herpes simplex virus (Imlygic®) for the treatment of
melanoma [1]. Moreover, a recent clinical report demon-
strating that OVT can improve the efficacy of the anti-PD-1
immune checkpoint antibody, pembrolizumab, increases
their potential clinical applicability [2]. Oncolytic viruses
(OVs) can utilize two distinct mechanisms to induce their
anti-tumor effects, namely: 1) direct cytotoxicity (oncolysis)
following replication and lytic killing of tumor cells [3–5],
and 2) induction of anti-tumor immunity, which can be me-
diated by innate and adaptive immune mechanisms [6–8].
Specifically, OVs alter the tumor microenvironment through
the induction of pro-inflammatory cytokines and a reduc-
tion in immunosuppressive factors, such as VEGF and IL-
10. Furthermore, OVs enhance natural killer (NK) cell-
mediated tumor killing [9–12] and stimulate the generation
of cytotoxic T lymphocytes (CTLs) through the release of
tumor-associated antigens (TAAs), with OVs providing the
immunological “danger” signal [8, 12–14]. TAAs are subse-
quently processed by antigen-presenting cells (APC) and
presented to CD4+ T cells, or cross-presented to CD8+ T
cells, to promote an adaptive immune response, including
immunological memory, against the tumor [15, 16]. Despite
numerous efforts to enhance the direct lytic potential of
OVT, including suppression of host immune responses, the
induction of anti-tumor immunity has emerged as a pivotal
mechanism for long-term clinical efficacy [17].
The Kuykendall strain of coxsackievirus A21 (CVA21)
was manufactured to clinical grade (CAVATAK®) by Vira-
lytics Ltd. and was recently acquired by Merck/MSD.
CVA21 has been tested in a number of clinical trials [18–
20] and, like Imlygic®, CAVATAK® has yielded promising
results in the treatment of melanoma and other solid tu-
mors [21, 22]; a Phase I clinical trial (STORM; Systemic
Treatment Of Resistant Metastatic disease) of intraven-
ously administered CAVATAK® in combination with pem-
brolizumab is ongoing [18]. CVA21 may cause mild upper
respiratory tract infection in immunocompetent adults
and approximately 15% of the population possess pre-
existing antibodies against CVA21 [22, 23]. CVA21, an en-
terovirus belonging to the family Picornaviridae, has a
positive-sense single-stranded RNA genome and utilizes
Decay Accelerating Factor (DAF) to bind to host cells and
Intercellular Adhesion Molecule 1 (ICAM-1) for internal-
ization. Thus, overexpression of ICAM-1, observed on
many malignantly transformed cells, can serve as a pre-
dictor of tumor cell susceptibility to CVA21-mediated
oncolysis [3, 24, 25]. However, the inability of CVA21
to infect mouse cells has limited testing of its immuno-
therapeutic potential in immune-competent pre-clinical
animal models.
Currently, OVT remains relatively under-investigated in
the context of hematological malignancies with the major-
ity of studies focusing on their direct lytic potential [26–
29]. As such, the role for OV-induced immunotherapy, in
potentially immunocompromised patients, is less clear. To
date, preclinical studies have evaluated a small selection of
OVs for the treatment of AML, including myxoma virus
[26], vesicular stomatitis virus (VSV) [30], reovirus [6] and
herpes simplex virus-1 (HSV-1) [31]; however, disappoint-
ingly, only one OV, VSV genetically modified to express
IFN-β and sodium iodide symporter genes, has progressed
to early clinical trials [32]. By contrast, the role for OVs in
the treatment of multiple myeloma (MM) is more estab-
lished with multiple clinical trials ongoing or completed
[33]. Both AML and MM are in need of novel therapeutic
interventions which are safe and well-tolerated, such as
OVT [34, 35]. Therefore, we examined the immunothera-
peutic potential of CVA21 against AML, which was rela-
tively non-permissive to CVA21 infection and oncolysis,
and MM, which was sensitive to CVA21-induced oncoly-
sis. This study provides pivotal insight into: 1) the poten-
tial for CVA21-induced anti-tumor immunity against
hematological malignancies; 2) the immunotherapeutic
properties of CVA21; and 3) the cellular requirements for
CVA21-induced anti-tumor immunity.
Methods
Cell culture and patient samples
All cell lines were grown according to ATCC/ECACC rec-
ommendations and ICAM-1-expressing KG-1 cells (ICAM-
1/KG-1) were generated using lentiviral transduction.
Peripheral blood mononuclear cells (PBMC), obtained
from healthy volunteers or leukocyte apheresis cones
(National Health Service Blood and Transplant), were
isolated using Lymphoprep™ (Fresenius-Kabi AS, Hal-
den, Norway) density-gradient centrifugation as previ-
ously described [7]. PBMC were used at 2 × 106 cells/mL
and PBMC-conditioned medium (CM), collected 48 h
after CVA21 treatment, was stored at − 20 °C prior to
use. For type I IFN neutralisation, PBMC were pre-
incubated for 30 mins with polyclonal antibodies prior
to addition of CVA21 for 24 h [10]. For ICAM-1 block-
ade, PBMCs were either treated with 10 μg/mL LEAF™
purified anti-human ICAM-1-blocking antibody, a
mouse IgG1-isotype control antibody (both BioLegend),
or left untreated for 30 min at 37 °C. Subsequently, the
PBMC were exposed to CVA21 for 24 h, before evalu-
ation of NK cell activation and cytokine secretion.
Blood samples were obtained from patients diagnosed
with AML or patients taking part in the STORM Phase 1
clinical trial (NCT02043665/Keynote-200/VLA009A) fol-
lowing additional informed consent. Written, informed
consent was obtained from all patients in accordance with
local institutional ethics review and approval (06/Q1206/
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106). Peripheral blood samples collected from patients re-
cruited into the STORM clinical trial were collected from
Cohort 1 and 3 (Cycle 1), who received 1 × 108 or 1 × 109
TCID50 clinical grade CVA21, respectively. Samples were
collected prior to the first CVA21 infusion in Cycle 1, then
at 1 h, 3 days and 22 days after the first infusion; samples
collected on day 3 and 22 were taken before scheduled
CVA21 treatments.
CD14+ monocytes and plasmacytoid dendritic cells
(pDC, Lin−, BDCA-2+, BDCA-4+, CD123+, CD4+,
CD45RA+, BDCA-3dim, BDCA-1−, CD2−) were isolated or
depleted from whole PBMC using magnetic cell sorting
on MACS® columns (Miltenyi Biotec, Bergish Gladbach,
Germany), according to the manufacturer’s instructions.
PBMC (±CD14+ monocytes or pDC) were used for collec-
tion of CM, assessment of NK cell activation and for CTL
priming assays (see below).
Gene expression analysis
mRNA was isolated using the RNeasy Plus kit (Qiagen,
Hilden, Germany) and converted to cDNA using the
SuperScript™ III Reverse Transcriptase kit and oligoDT
priming (Thermo Fisher Scientific, Waltham, MA). Gene
expression was evaluated by qPCR using TaqMan™ re-
agents and the QuantStudio 5 Real-Time PCR System
(Thermo Fisher Scientific, Waltham, MA).
Coxsackievirus A21
Wild-type coxsackievirus A21, Kuykendall strain, was
provided by Viralytics Ltd. (Sydney, Australia) or propa-
gated in-house from wild-type CVA21 obtained from
ATCC® (ATCC®VR-850™). For propagation, supernatants
were harvested following CVA21 infection of Mel624
cells for 24 h. CVA21 was pelleted by centrifugation at
36000 rpm for 2 h (SW45 rotor, Optima™ L-80 ultra-
centrifuge, Beckman Coulter) and harvested virus was
purified using OptiPrep™ density gradient centrifugation,
35–15% gradient (36,000 rpm, 1.5 h, SW41 Ti rotor).
Viral titer was determined using a standard plaque assay
on Mel624 cells.
MTS assay
MTS assays were performed according to the manufac-
turer’s protocol (Abcam, Cambridge, UK). Optical dens-
ity was measured at 450 nm using a Multiscan EX
microplate reader (Thermo Fisher Scientific).
Cytokine detection
IFN-α secretion was detected using matched paired anti-
bodies (MabTech AB) and standard ELISA techniques.
PBMC-CM was also analyzed using multiplex bead arrays
(Bio-Plex Pro™ Human Cytokine 27-plex and 23-plex
Assay; Bio-Rad) as per the manufacturer’s instructions.
Plates were analyzed using a Bio-Plex 100 reader with Bio-
Plex Manager software.
Priming of AML-specific cytotoxic T cells
Immature DC (iDC) generation and CTL priming assays
were performed as described by Prestwich et al [8].
Briefly, tumor cells (±0.1 pfu/cell CVA21 for 24 h) were
loaded onto CD14+ monocyte-derived iDC and co-
cultured with autologous PBMC for 1 week. CTL were
then re-stimulated with tumor-loaded iDC (±CVA21)
and cultured for a further 7 days. Primed CTL were then
harvested for 51Cr release assay, CD107 degranulation or
peptide recall assays.
Where indicated, CTL generation was also performed in
the absence of iDC, using only CVA21-treated tumor cells.
To do this, CVA21-infected tumor cells, treated with 0.1
pfu/cell CVA21 for 24 h, were centrifuged to remove free
virus, and incubated for a further 48 h prior to addition of
PBMC. PBMC were cultured for 1 week and re-stimulated
with tumor cells (±CVA21 treatment – as above).
For TAA peptide stimulation, autologous CD14+ cells
were thawed from frozen, washed with medium, and
allowed to rest for 60 min prior to incubation with 6
nmol/mL PepTivator® peptide pools (15-mer peptide se-
quences with 11 amino acids overlap, Miltenyi Biotec)
for 60 min at 37 °C; PepTivator® Peptide Pools were
reconstituted in dH2O at 30 nmol/mL and aliquots were
stored at − 80 °C. Autologous CD14+ cells with or with-
out PepTivator® peptide loading were then co-cultured
with CTL and intracellular IFN-γ production was deter-
mined by flow cytometry.
Flow cytometry analysis
For all flow cytometry analysis, cells were stained with
relevant antibodies (see Additional file 1: Table S1 and
analysis was performed on an Attune® Acoustic Focusing
Cytometer (Thermo Fisher Scientific) or CytoFLEX S
(Beckman Coulter). Cell viability was evaluated using a
LIVE/DEAD® Fixable Dead Cell Stain Kit (Thermo
Fisher Scientific). For NK cell and CTL CD107 degranu-
lation assays, PBMC were co-cultured with target cell
lines (2:1 ratio) for 1 h. Following this, Brefeldin A (1:
1000, BioLegend, San Diego, CA) and relevant anti-
bodies (see Additional file 1: Table S1) were added to
each sample for 4 h. For intracellular IFN-γ staining,
CTLs were co-cultured with target cells (2:1 ratio) or au-
tologous CD14+ cells (±PRAME, Mucin-1 and MAGE-
A1 peptide pools) for 1 h at 37 °C before addition of Bre-
feldin A (1:1000, BioLegend) and relevant antibodies
(Additional file 1: Table S1) for a further 4 h at 37 °C.
CTLs were then fixed in 1% paraformaldehyde (PFA)
overnight and permeabilized using 0.3% saponin (Sigma-
Aldrich) prior to intra-cellular IFNγ staining and acqui-
sition by flow cytometry.
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51Cr release assay
Target cells were labelled with 100 μCi 51Cr (PerkinEl-
mer, Waltham, MA) then co-cultured with effector cells
as previously described [6]; unlabeled K562 and Daudi
cells were included in the analysis of CTLs to reduce
non-specific killing. For NK cell 51Cr release assays, the
data shown represents the effector:target ratio of 50:1
for AML (0.1pfu/cell CVA21), and 25:1 for MM (1pfu/
cell). 51Cr was measured using a Microbeta2 scintillation
counter (PerkinElmer) and the percentage cell lysis was
calculated (cpm: counts per minute):
%lysis ¼ 100 sample cpm−spontaneous cpm
maximum cpm−spontaneous cpm
Statistical analysis
Statistical analysis was performed using Graphpad Prism
7.0 software. p-values were calculated using either Student’s
t-test, one-way analysis of variance (ANOVA) or two-way
ANOVA. Results were considered significant if p < 0.05
(* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001).
Pearson’s r was calculated to evaluate correlations.
Results
Activation of immune effector cells in vivo following
intravenous (i.v.) administration of CVA21
As CVA21 is dependent on human ICAM-1 for cell entry,
only human model systems or immunocompromised hu-
man xenograft murine models allow in vivo testing of
CVA21, with the latter preventing exploration of the role
of adaptive anti-tumor immunity. Therefore, to initially
confirm the immunotherapeutic potential of CVA21 in
vivo, and in potentially immunosuppressed cancer pa-
tients [36–39], we took advantage of access to samples
from STORM (VLA009A) clinical trial patients. This
Phase I dose escalation study examined the safety of i.v.
delivery of CVA21 to patients with mixed types of ad-
vanced cancers including melanoma, prostate and squa-
mous cell carcinoma of the lung (Fig. 1a). STORM
patients that consented to have additional research blood
samples taken for analysis received 1 × 108 (Cohort 1) or
1 × 109 TCID50 (Cohort 3) clinical grade CVA21 on days
1, 3 and 5 (Cycle) and blood samples were collected prior
to the first CVA21 infusion, then at 1 h, 3 days and 22 days
after the first infusion (Fig. 1b). No consistent increase in
IFN-α secretion, a key mediator of host anti-viral and
anti-tumor responses, was observed in the patient plasma
samples at these time points (data not shown). However,
using qPCR, we observed an increase in the expression of
interferon-stimulated genes (ISG), IFIT1, IFI44L and
OAS1, 3 days after the first CVA21 infusion, compared
with the baseline pre-infusion samples (Fig. 1c); this was
more pronounced in patients who received a higher dose
of virus and suggested the onset of a type I IFN response
in the peripheral blood of CVA21-treated patients.
To analyze the effect of CVA21 on immune effector cells,
the expression of CD69 (an early marker of lymphocyte ac-
tivation) on NK cells, CD4+ T cells and CD8+ T cells was
examined at each time point; a peak in immune cell activa-
tion was identified on day 3 (Fig. 1d-f). Stronger activation,
particularly of NK cells (Fig. 1d), was observed in Cohort 3
where a higher dose of CVA21 was administered. Encour-
agingly, these data demonstrate that i.v. administration of
CVA21 can induce a type I IFN response and activate im-
mune cells in the peripheral blood of cancer patients. Im-
portantly, data presented in Additional file 2: Figure S1 also
demonstrate that CVA21 treatment is not toxic to healthy
donor (HD) PBMC, and that HD-PBMC do not support
CVA21 viral replication, in vitro.
Having confirmed that CVA21 could stimulate immune
activation in patients, we wanted to further characterize
the immunomodulatory properties of CVA21, and estab-
lish the role of CVA21-induced immunotherapy. To do
this we first sought to identify models of disease which
were sensitive or resistant to CVA21-induced direct onco-
lysis for use in established immunological assays. We
identified AML cell lines, which expressed low levels of
ICAM-1, as relatively insensitive to CVA21-induced direct
oncolysis (see Additional file 3: Figure S2A and B, respect-
ively), and MM cell lines (except OPM2), which expressed
higher levels of ICAM-1, as highly susceptible to CVA21
oncolysis (see Additional file 3: Figure S2C and D, respect-
ively).
Pro-inflammatory cytokines induce bystander killing of
CVA21-resistant cells
The induction of ISGs following i.v. infusion of CVA21
implies an interferon response, and IFN-α2 has known
cytotoxic potential against both AML and MM, with mul-
tiple IFN-α-based clinical trials having been completed
[40, 41]. To date, the inflammatory milieu induced by
CVA21 has not been thoroughly explored; moreover, its
potential role in CVA21 efficacy remains unknown. To
initially investigate this, we used a multiplex assay to
examine the range of cytokines and chemokines induced
from HD-PBMC following CVA21 treatment. These data
confirmed that CVA21 elicited a strong cytokine response
(Fig. 2a), with a number of potentially cytotoxic cytokines,
including IFN-α2, TRAIL and IFN-γ, being identified.
Having previously identified KG-1, HL-60, kasumi-1 and
OPM2 cells as resistant to CVA21-direct oncolysis (Add-
itional file 3: Figure S2B and D) these cells were subse-
quently used to examine the cytotoxic potential of
CVA21-induced inflammation. KG-1, HL-60, kasumi-1
and OPM2 cells were cultured in PBMC-CM (±CVA21
treatment) for 96 h and cell viability was examined;
CVA21-treated PBMC-CM significantly reduced the
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viability of all CVA21-resistant cell lines (Fig. 2b), which,
given resistance to CVA21-direct oncolysis, was highly
suggestive of CVA21-induced bystander cytokine killing.
In support of this, reconstitution of culture media with re-
combinant IFN-α or IFN-γ (cytokines secreted in response
to CVA21 treatment) also demonstrated a small, but sig-
nificant, increase in killing of CVA21-resistant KG-1 cells
(Additional file 4: Figure S3A).
Conversely, an alternative explanation for the death in-
duced by PBMC-CM was a possible up-regulation of
Fig. 1 Intravenous CVA21 induces a type I IFN response and activates immune effector cells in vivo. a. As part of the STORM clinical trial, patients
(n = 5) with advanced malignancies were administered with 1 × 108 (red symbols) or 1 × 109 TCID50 (black symbols) clinical grade CVA21 i.v. b.
CVA21 was infused on day 1, 3 and 5 and blood samples were taken pre-infusion (a), 1 h (b), 3 days (c) and 22 days (d) after the first infusion. c.
cDNA was made from PBMC collected pre-infusion (a) and on day 3 (c) and the expression of IFIT1, IFI44L and OAS1 was measured by qPCR.
Results were normalized to 18S RNA expression and the fold increase in expression (calculated as ΔΔCt) compared to pre-infusion is presented.
d-f CD69 expression on NK cells (d), CD4+ T cells (e) and CD8+ T cells (f) was analyzed at each time point. *denotes statistical significance
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ICAM-1, which could ultimately confer susceptibility to
CVA21-direct oncolysis. Indeed, we did observe a modest
increase in ICAM-1 expression on cells treated with
CVA21-treated PBMC-CM (up to 4-fold – data not shown)
. Therefore, to explore this possibility we used TNF-α, a
known up-regulator of ICAM-1, and re-examined CVA21-
direct oncolysis and assessed viral replication following
TNF-α treatment. These results demonstrated that both
THP-1 and Kasumi-1 cells remained resistant to CVA21-
direct oncolysis despite a greater than 10-fold increase in
ICAM-1 expression (Additional file 4: Figure S3B and C);
moreover, plaque assays confirmed that there was no in-
crease in CVA21 titre, compared to input virus, 72 h post-
infection (data not shown). In addition, we also examined
viral replication (by plaque assay) in CVA21-resistant
THP-1 and Kasumi-1 cells following treatment with
PBMC-CM (to increase ICAM- expression); similarly, no
increase in viral titre was observed 72 h post infection
(data not shown).
By contrast, KG-1 cells became susceptible to CVA21-
direct oncolysis in accordance with increased ICAM-1 ex-
pression (Additional file 4: Figure S3D and E); suggesting
that death of KG-1 cells (Fig. 2b) could, in part, be medi-
ated by increased ICAM-1 expression following treatment
with CVA21 treated PBMC-CM, which incorporates a
range of inflammatory cytokines, including TNF-α. Inter-
estingly, complimentary studies carried out using ICAM-1
transduced KG-1 cells (ICAM-1/KG-1), to remove pos-
sible off-target effects of TNF-α, examined CVA21 suscep-
tibility in the presence of anti-viral type I IFN-α2 (at levels
comparable to those identified in CVA21-treated PBMC-
CM); these studies demonstrated a small increase in cyto-
toxicity following IFN-α treatment alone (as observed in
Additional File 4: Figure S3A) but a significant abrogation
of CVA21-direct oncolysis (Additional file 4: Figure S3F).
Therefore, overall we believe that the inherent resist-
ance of some cell lines to CVA21 (despite high levels
of ICAM-1), the abrogation of CVA21-direct oncolysis
Fig. 2 CVA21 treatment induces cytokine-mediated bystander killing of CVA21-resistant cells. a. Conditioned-media (CM) was collected from
healthy donor PBMC after 48 h (±CVA21 treatment; 1 pfu/PBMC) and analyzed for cytokines using a 48-plex multiplex assay. The mean fold
change (n = 3) compared to untreated PBMCs is shown. Sample readings outside of the detection range were estimated using the assay range
limits and are indicated by x. b. CVA21-resistant cell lines were cultured for 96 h in PBMC-CM (0, 0.1 and 1 pfu/cell CVA21 treatment for 48 h; n =
6 for KG-1, HL-60 and OPM2, n = 5 for kasumi-1) and cell viability was assessed using an MTS assay. Error bars indicate SEM. *denotes
statistical significance
Müller et al. Journal for ImmunoTherapy of Cancer           (2019) 7:164 Page 6 of 16
by type I IFN-α (present in CVA21-treated PBMC-
CM), and the direct cytotoxic potential of CVA21-
induced cytokines, are more suggestive of bystander
cytokine killing and indicate that the inflammatory
changes stimulated by CVA21 treatment could con-
tribute to CVA21-induced immunotherapy.
CVA21-mediated activation of NK cells and potentiation
of cellular cytotoxicity
We have previously shown that OV-induced type I IFN-α
can increase the anti-tumor properties of NK cells [7],
therefore given that CVA21 stimulated IFN-α in vitro (Fig.
2a), and activated NK cells in vivo (Fig. 1d), we examined
the ability of OV-activated NK cells to eradicate CVA21-
sensitive and CVA21-resistant cells. Initially we confirmed
that CVA21 could activate NK cells, in vitro, and demon-
strated that treatment of HD-PBMCs with CVA21 in-
duced a significant increase in CD69 expression on NK
cells, as expected (Fig. 3a). Pivotally, this heightened state
of NK cell activation was associated with improved recog-
nition and killing of both CVA21-sensitive (H929, U266B
and JIM3) and CVA21-resistant (AML cell lines and
OPM2) cell targets, as measured by CD107a/b expression
(Fig. 3b) and chromium release (Fig. 3c), respectively. This
confirmed the ability of CVA21 to induce NK cell medi-
ated anti-tumor immunity.
Priming of tumor-specific cytotoxic T cells using CVA21
While innate immunity is rapid and instrumental for the
eradication of tumor cells, generation of adaptive anti-
tumor immunity is necessary for long-term immunological
memory. The activation of both CD4+ and CD8+ T cells in
cancer patients following CVA21 treatment (Fig. 1e and f)
suggests the induction of a T cell immune response; how-
ever, its relationship to anti-viral and/or anti-tumor im-
munity is unclear. To evaluate the ability of CVA21 to
stimulate the production of tumor-specific CTLs, we
adapted our previously established protocol for OV CTL
priming [8], to the hematological setting. This protocol in-
volved long-term co-culture of CVA21-infected tumor cell
targets, pre-loaded onto myeloid-derived dendritic cells
(mDC), with PBMC autologous to the tumor-loaded mDC
[8]. We initially examined the ability of CVA21 to stimulate
CTL priming using CVA21-sensitive cells (U266B MM
cells and ICAM-1/KG-1 AML cells) which, following direct
oncolysis, should release damage-associated molecular pat-
terns (DAMPs) and pathogen-associated molecular pat-
terns (PAMPs) to activate mDC and facilitate CTL priming.
Firstly, we identified that for efficient CTL priming, and
lysis of relevant cell targets, the presence of CVA21 was re-
quired (Fig. 4Ai and Bi); moreover, primed-CTL were
tumor specific, as only relevant, but not irrelevant, target
cells were capable of stimulating intracellular IFN-γ pro-
duction (Fig. 4Aii and Bii).
Next, to explore the antigen recognition repertoire of the
primed-CTLs, we examined their responsiveness towards a
known LAA (leukemia-associated antigen), Mucin-1 and
Melanoma-associated antigen (MAGE)-A1 expressed by
U266B cells [42], and PRAME (PReferentially expressed
Antigen in Melanoma), expressed by KG-1 cell targets [43].
To do this, primed-CTLs were co-cultured with autologous
CD14+ cells, pre-loaded with appropriate peptide pools,
and intracellular IFN-γ production was quantified by flow
cytometry. This readout allows tracking of T cell responses
against known TAA/LAA without HLA restriction; autolo-
gous monocytes process and present peptides, which span
the full length antigen, for stimulation of antigen-specific T
cells and IFN-γ production. Although, as expected, inter-
donor variation was observed, antigen-specific CTLs recog-
nizing: 1) Mucin-1 and MAGE-A1, after priming with
U266B cells, and 2) PRAME, after priming with ICAM-1/
KG-1 cells, were identified (Fig. 4aiii and biii).
We have previously demonstrated, using an alternative
OV, reovirus, that anti-tumour immunity can occur inde-
pendently of direct oncolysis [44], therefore, to determine
if CVA21-mediated oncolysis was required for the suc-
cessful generation of CTLs, priming assays were repeated
using parental-KG-1 and THP-1 cells which, by compari-
son to ICAM-1/KG-1 and U266B cells, were relatively
non-permissive to CVA21 infection and oncolysis; for ex-
ample, no evidence of viral replication or cell death was
observed in THP-1 cells, and only low level replication (~
130 fold increase in titre at 72 h) and cell death (~ 10% in-
crease at 1pfu/cell) was observed in KG-1 (data not shown
and Additional file 3: Figure S2B, respectively). Interest-
ingly, these data demonstrate that tumor-specific CTLs
were produced for both parental-KG-1 and THP-1 cell
targets (Fig. 4C), indicating that CVA21-induced oncolysis
(particularly for THP-1 cells) was not a pre-requisite for
the generation of long-term anti-tumor immunity, as pre-
viously observed for reovirus [44].
CVA21 maturation of mDC
Given the efficient CTL priming demonstrated in Fig. 4, it
was postulated that CVA21 would induce DC maturation
following co-culture with CVA21-infected cell targets, and
thus provide the necessary antigen presentation and co-
stimulation to support efficient CTL priming. Surprisingly,
upon phenotyping of mDC following treatment with
CVA21 alone, or CVA21-loaded targets, limited mDC mat-
uration was observed; CVA21 was unable to directly stimu-
late mDC maturation and only modest maturation (a small
but significant increase in CD86 expression) was observed
upon co-culture of mDC with CVA21-treated ICAM-1/
KG-1 (Fig. 5a). Therefore, the importance for mDC during
the course of the CTL priming assay was examined. To in-
vestigate this, we compared the ability of CVA21 to prime
tumor-specific CTLs in the presence or absence of ex vivo
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generated, tumor-loaded, mDC. Figure 5b shows that
CTLs primed with or without mDC were comparable
in their capacity to lyse relevant tumor cell targets,
demonstrating that CVA21-treated tumor cells can
support CTL priming, irrespective of the presence or
absence of mDC. Importantly, the CTLs generated in
the absence of mDC retained their tumor specificity
as CTL degranulation was only observed upon
recognition of relevant, but not irrelevant, cell targets
(Fig. 5c). Collectively, these data confirmed that in vitro
generated mDC were not required for successful CTL
priming, and suggested that all cellular components re-
quired for adaptive CTL priming, by CVA21-treated
tumor cells, were present in the peripheral blood. This
finding is of particular importance in the context of
hematological malignances as CVA21-loaded tumor cells
Fig. 3 CVA21 treatment enhances NK cell activation and function. a. CD69 expression on healthy donor NK cells (CD3−CD56+) following CVA21
treatment for 48 h (n = 4). b. Healthy donor PBMC (± 0.1 pfu/cell CVA21) were co-cultured at a 2:1 ratio with AML or MM target cells for 5 h and
the percentage of NK cells expressing CD107a/b was determined (n = 4); data for CVA21-sensitive (right) and CVA21-resistant (left) cell lines are
shown. c. CVA21-sensitive (right) and CVA21-resistant (left) cell lines were labelled with 51Cr and then co-cultured with healthy donor PBMC (±
CVA21 treatment) for 4 h and the percentage lysis of target cells was determined (n = 4). Error bars indicate SEM. *denotes statistical significance
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may co-exist, in the blood, with immune cell components
that are necessary for effective CTL priming.
ICAM-1 expression on immune cells is required for the
induction of CVA21 anti-tumor immunity
Data presented in Figs. 1, 2, 3, 4 and 5 demonstrate that
CVA21 can activate innate and adaptive anti-tumor
immunity against tumor cells which are both sensitive
and resistant to CVA21-direct oncolysis; moreover, it
appeared that all the cellular components required for
this to occur were present in the blood. Therefore, to
identify potential biomarkers of CVA21 response we
sought to further characterize the molecular and cellular
determinants required for CVA21-mediated immune
Fig. 4 CVA21 can prime tumor-specific CTL. a. and b: CVA21-sensitive U266B MM (a) and ICAM-1/KG-1 (b) cell targets were used. Tumor cells
were pre-treated with CVA21 (0.1 pfu/cell) for 24 h, then loaded onto mDC prior to being co-cultured with autologous PBMC and one round of
re-stimulation. a. and bi. CTLs primed in the presence or absence of CVA21 were co-cultured with 51Cr-labelled relevant targets (U266B and
ICAM-1/KG-1 cells, respectively) at different effector:target ratios for 4 h. The percent cell lysis was determined using 51Cr release (n = 6). a. and bii.
CTL intracellular IFN-γ production following a 5 h co-culture with relevant (U266B or ICAM-1/KG-1, respectively) or irrelevant (ICAM-1/KG-1 or Raji,
respectively) targets (n = 3). a. and biii. Intracellular IFN-γ production following a 5 h co-culture with autologous CD14+ cells loaded with
appropriate peptide pools (Mucin-1 and MAGE-A1; U266B CTLs, and PRAME; ICAM-1/KG-1 primed CTLs). c. CTL priming with CVA21-resistant cells
(parental-KG-1 (i) and THP-1 (ii)). The percentage of tumor specific CTLs (CD3+CD8+) was determined using CD107a/b degranulation after a 5 h
co-culture with relevant (KG-1; n = 3 or THP-1; n = 2) or irrelevant (Raji) cell targets. Spontaneous CD107 expression was subtracted from the
values shown. Error bars indicate SEM. *denotes statistical significance
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activation. Our preliminary studies suggested that CVA21
was unable to directly activate isolated NK cells (data not
shown), therefore, in the context of PBMC, we initially ex-
amined the role of anti-viral type I IFN for the induction
of CVA21-mediated NK cell anti-tumor immunity. Using
monoclonal type I IFN-blocking antibodies, we confirmed
that NK cell activation was mediated by type I IFNs, as
NK cell CD69 upregulation (Fig. 6a) and increased NK cell
degranulation (Fig. 6b), following CVA21 treatment of
PBMC, was not observed when type I IFN signaling was
inhibited. Moreover, following this the importance of
ICAM-1 (required for CVA21 infection of tumor cells [24])
on immune cell components was investigated; blockade of
ICAM-1 within PBMC, prior to and during CVA21 treat-
ment, completely abrogated the secretion of IFN-α (Fig. 6c)
and prevented NK cell activation (no increase in CD69 ex-
pression; Fig. 6d) demonstrating a significant role for
ICAM-1 in mediating CVA21-induced immune activation.
To further elucidate the role for ICAM-1 (on tumor cells
or immune effectors) in coordinating CVA21 efficacy, we
took advantage of AML patient samples (see Additional file 5:
Table S2). Ex vivo treatment of primary AML blasts with
CVA21 identified a number of patients (n = 8 of 16) whose
blasts were susceptible to CVA21 killing (see Additional file 6:
Figure S4A), whilst CD45+ hematopoietic non-malignant
cells remained unharmed (Additional file 6: Figure S4B). Ini-
tially, to explore whether CVA21 efficacy was dependent on
direct oncolysis we examined the association between
CVA21-induced death and ICAM-1 expression on malig-
nant AML blasts; interestingly, no correlation was observed
(Pearson’s r = 0.122, see Additional file 6: Figure S4C). Fur-
thermore, no detectable viral replication was observed in
nine out of the 10 samples tested, with only low-level viral
replication observed in one sample (data not shown). Whilst
disappointing in terms of the capacity of CVA21 to directly
infect and lyse AML cells, these data were in accordance
with our in vitro cell line data (see Additional file 3: Figure
S2B and Additional file 4: Figure S3C) which suggested that
AML cell lines were relatively non-permissive to CVA21-
direct oncolysis.
Fig. 5 mDC are not necessary for priming of AML-specific CTL. a. mDC were treated with CVA21 or CVA21-treated ICAM-1/KG-1 cells for 48 h and
expression of the activation markers, CD86, CD80 or HLA-DR, was examined (n = 4). b. ICAM-1/KG1-specific CTLs were primed with or without
autologous mDC (±CVA21) and CTL-mediated lysis of relevant ICAM-1/KG-1 targets was measured by 51Cr release assay. Solid lines indicate CTL
primed in the presence of mDC, dashed lines indicate CTL primed in the absence of mDC (n = 3). c. ICAM-1/KG1 CTLs, primed in the absence of
mDC, were co-cultured with relevant (ICAM-1/KG-1) or irrelevant (Raji) target cells (n = 3) for 5 h and tumor specificity was examined using
CD107a/b degranulation. Error bars indicate SEM. *denotes statistical significance
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Given the capacity of CVA21 to induce innate and adap-
tive anti-tumor immune responses (Figs. 1, 2, 3, 4 and 5), it
was therefore postulated that the immunotherapeutic prop-
erties of CVA21 could be responsible for death of primary
AML blasts. In support of this we have demonstrated that:
patient-derived, CVA21-treated PBMC-CM was cytotoxic
against AML cell lines (Additional file 6: Figure S4D); IFN-
α, which stimulates immune cell activation but abrogates
CVA21-direct oncolysis, was induced in CVA21 treated
AML patient samples (Additional file 6: Figure S4E); patient
NK cells were activated by CVA21 to increase CD69 ex-
pression (Additional file 6: Figure S4F); and that NK cell ac-
tivation correlated with IFN-α production (Pearson’s r =
0.74, p = 0.0009; Additional file 6: Figure S4G). Further-
more, ICAM-1 expression on non-malignant CD45+ im-
mune effector cells within patient samples (Fig. 6e)
Fig. 6 Type I IFN and ICAM-1 are required for CVA21-induced anti-tumor immunity. a-d. HD-PBMC were treated with CVA21 for 24 h, with or
without pre-treatment with type-1 IFN blockade or an ICAM-1-blocking antibody. NK cell CD69 expression (a) and NK cell CD107a/b
degranulation (b) were measured in the presence of type I IFN blocking antibodies or corresponding isotype antibodies (n = 4). c. HD-PBMC were
treated with CVA21, in the presence or absence of ICAM-1-blocking antibodies, and IFN-α secretion was examined by ELISA (n = 3). d. NK cell
CD69 expression was determined following CVA21treatment, with or without pre-treatment with an ICAM-1-blocking antibody or isotype control
(n = 3). e. ICAM-1 expression was measured on mature hematopoietic immune cells (CD45+) from primary AML patients (n = 14). f. Correlation of
CVA21 response (death of AML blasts) with ICAM-1 expression on mature CD45+ hematopoietic cells from primary AML samples. Error bars
indicate SEM. *denotes statistical significance
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significantly correlated with the efficacy of CVA21 (death of
patient AML blasts) in these primary patient samples (Pear-
son’s r = 0.67, p = 0.009; Fig. 6f). Therefore, within a mixed
cell population, comprising patient AML blasts with au-
tologous non-malignant CD45+ immune effector cells, the
susceptibility of AML cells to CVA21 treatment was deter-
mined by ICAM-1 expression on immune effector cells,
not the malignant AML compartment. Thus, whilst the
exact immune mechanisms responsible for CVA21 cytotox-
icity towards AML blasts have not been defined, these data
support a role for CVA21-induced immunotherapy for
CVA21 efficacy in AML patient samples, and demonstrated
the importance of ICAM-1 in mediating this immune
response.
Plasmacytoid dendritic cells (pDC) are essential for
induction of CVA21-mediated anti-tumor immunity
As ICAM-1 was identified as a key mediator of
CVA21 anti-tumor immunity, we next sought to iden-
tify the immune cell component responsible for
CVA21 recognition, and downstream immune activa-
tion. Initially, we identified both monocytes (CD14+)
and pDC as cell populations which expressed signifi-
cantly more ICAM-1 than NK cells, CD4+ and CD8+
T cells (Fig. 7A), therefore, we hypothesized that these
two cell types may act as key regulators of CVA21-
mediated anti-tumor immunity. To test this, we first
examined IFN-α production (a key mediator of NK
cell activation; Fig. 6) from PBMC depleted of CD14+
monocytes, pDC, or both (CD14+ cells and pDC),
along with isolated CD14+ monocytes and pDC. Fig-
ure 7B demonstrates that pDC, in isolation, secreted
large amounts of IFN-α following CVA21 treatment,
and that IFN-α secretion from PBMC was abrogated
following pDC depletion. By contrast, CD14+ deple-
tion had no significant effect on IFN-α levels follow-
ing CVA21 treatment, and isolated CD14+ cells did
not secrete IFN-α in response to CVA21 treatment.
To further examine the role of monocytes and pDC
for anti-tumor immunity, we repeated PBMC-CM
toxicity, NK cell activation and degranulation assays,
as well as T cell priming experiments but depleted
CD14+ monocytes, pDC, or both, from the whole
PBMC population. Interestingly, CVA21-treated
PBMC-CM remained toxic to kasumi-1 and HL-60
cells in the absence of CD14+ cells; however, when
PBMC were depleted of pDC, the cytotoxicity of
CVA21-treated PBMC-CM was reduced to levels
comparable with untreated PBMC-CM (Fig. 7C).
Moreover, the absence of IFN-α following pDC deple-
tion (but not monocyte depletion), abrogated CVA21-
induced NK cell activation with regards to both CD69
up-regulation, and enhanced NK cell degranulation
(Fig. 7D). Furthermore, CTL priming assays (per-
formed without the addition of autologous mDC) also
revealed the importance of pDC, as the absence of
CD14+ did not significantly decrease the production
of tumor-specific CTLs; however, removal of pDC sig-
nificantly reduced levels of tumor-specific CTL (Fig.
7E). Taken together, these results demonstrate, for the
first time, the critical role of pDC in orchestrating
CVA21-induced innate and adaptive anti-tumor im-
mune responses and confirm the immunotherapeutic
potential of this agent.
Discussion
OVs represent a promising therapy for a wide range of
solid malignancies, but still remain an under-
investigated treatment option for hematological malig-
nancies, despite easy intravenous access to both tumor
and immune effector cells in these malignancies. The
results presented here demonstrate the potential for ef-
ficient OVT against both AML and MM, despite AML
cells being relatively resistant to CVA21-direct oncoly-
sis. We have demonstrated that CVA21 can potentiate:
1) innate anti-tumor immunity, mediated both by
cytokine-induced bystander killing and activation of
NK cells; and 2) adaptive anti-tumor immunity against
known TAA [45]. Mechanistically we have also demon-
strated the importance of ICAM-1 on immune cell
components, identified pDC as key orchestrators of
CVA21-induced immunotherapy, and established that
everything required to boost CVA21 immunity is avail-
able in the blood, which may be of particular signifi-
cance in the hematological disease setting. Importantly,
a role for CVA21-induced immunotherapy was also re-
vealed for tumor cells which were both sensitive and re-
sistant to CVA21-direct oncolysis, potentially widening
the clinical applicability of this agent. Whilst we do not
fully understand the mechanism/s by which CVA21
acts to boost CTL responses in less permissive tumor
cells, it is possible that viral attachment to cell surface
DAF (which is expressed by THP-1 and Kasumi-1; data
not shown) or ICAM-1 which is expressed, albeit at
low levels, facilitates immune activation and subsequent
priming of CTLs. Access to blood samples from cancer
patients taking part in the STORM (VLA009A) clinical
trial (a Phase I dose escalation study of i.v. CVA21) en-
abled us to explore immune changes that occur in the
blood following intravenous delivery of CVA21. These
studies showed that interferon-stimulated genes (ISG)
were induced 3 days after the first CVA21 infusion;
moreover, at day 3 CD69 expression on NK cells, CD4+
T cells and CD8+ T cells was also increased (Fig. 1d-f )
but decreased by day 22. Transient expression of CD69
on NK cells, associated with an IFN response, has pre-
viously been reported for reovirus, a dsRNA oncolytic
Müller et al. Journal for ImmunoTherapy of Cancer           (2019) 7:164 Page 12 of 16
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virus [11]. Currently, the exact function of CD69 on
lymphocytes remains unclear although CD69 has been
implicated in both cell adhesion/migration and nutrient
uptake. For example, CD69 expression can influence
the migration and retention of lymphocytes within
lymphoid tissue, and facilitate cell-to-cell interactions
with APC via Gal-1. Additionally, CD69 contributes to
the stability of LAT-1 (required for amino acid trans-
port) on the plasma membrane of lymphocytes to facili-
tate nutrient uptake to sustain the activation and
proliferation lymphocytes [46, 47]. The transient nature
of CD69+ lymphocytes in the blood of patients after
CVA21 treatment was not unexpected as CD69 is con-
sidered an early marker of lymphocyte activation which
can be induced quickly but also declines rapidly follow-
ing stimulation [46]. Unfortunately, as tumor biopsies
were not available during this study it is unclear
whether CD69+ lymphocytes persist in CVA21 treated
patients, at sites other than the blood (i.e. lymph node
and/or tumour), or whether CD69 was downregulated
on lymphocytes as a mechanism of immune control
once adaptive/humoral immunity had been appropri-
ately triggered.
The dependence on pDC for detection and initiation
of an immune response, resulting from abundant secre-
tion of IFN-α, is in contrast to other OVs, namely reo-
virus, where monocytes were identified as key detectors
in the peripheral blood [7], and could ultimately be used
to inform patient stratification and predict responsive-
ness to CVA21 therapy. For example, personalized medi-
cine approaches could be considered targeting patients
with normal to high pDC levels, or patients with high
expression of ICAM-1 on immune cell subsets and/or
malignant blasts. Both of which could be easily assessed
by flow cytometry on peripheral blood samples. Interest-
ingly, pDC are increased in the bone marrow of MM pa-
tients, and whilst they are believed to contribute to
immune cell dysfunction within the tumor microenvir-
onment, engagement of pDC pattern recognition recep-
tors (PRR), namely TLR-9, can restore pDC function
and promote T cell proliferation [48] - a concept worth
considering in the context of CVA21 engagement of al-
ternative PRRs.
Whilst the direct lytic potential of CVA21 against
primary AML was disappointing, the capacity of
CVA21 to modulate anti-tumor immunity in the ab-
sence of lytic killing remains encouraging for pa-
tients with a more competent immune system, such
as patients with MRD (minimal residual disease) or
early relapse, when disease burden may be low; pa-
tients in remission have a reconstituted immune re-
sponse with functional NK and T cells [49, 50].
Furthermore, to maximize OVT, the development of
novel combination approaches should be prioritized.
For example, combination with histone deacetylase in-
hibitors (HDACi), such as valproic acid (VPA), could
be evaluated to: 1) increase the expression of NKG2D
ligands on malignant blasts [51] and boost the cyto-
toxic effect of NK cells following OVT, or 2) syner-
gise with OVs to increase viral replication and
oncolysis [52]. In addition, hypomethylating agents, such
as decitabine, can increase the expression of TAAs [45],
therefore combination of CVA21 with different epigenetic
modulators may be advantageous to boost both innate
and adaptive anti-tumor immune mechanisms.
Conclusion
In summary, we have shown that CVA21 can trigger anti-
tumor responses against hematological malignancies.
Moreover, pDC are central to detection of the virus in the
circulation, and to subsequent priming of both the innate
and adaptive arms of the immune response. For successful
anti-TAA human CTL priming by CVA21-infected tumor
cells, PBMCs suffice as a source of APC and responder T
cells; therefore, in the context of hematological malignan-
cies treated by systemic OVT, all the cellular components
necessary for virus-mediated immunotherapy (including
the tumor cells as an antigen source, as well as responder
immune cells) are readily accessible. Overall, these data
support the testing of intravenous CVA21 for the treat-
ment of AML and MM, particularly in patients with a low
disease burden and, potentially, in combination with other
immunotherapies such as checkpoint inhibitors. Further-
more, the capacity of CVA21 to boost immunotherapeutic
responses, despite relative resistance to CVA21-direct
oncolysis, broadens the clinical applicability of this agent.
(See figure on previous page.)
Fig. 7 pDC orchestrate innate and adaptive CVA21 anti-tumor immunity. a. ICAM-1 expression on immune cell components from healthy donors
(n = 3). b-e CD14+ monocytes and pDC (CD123+BDCA-2+) were depleted from whole PBMC (W.PBMC) prior to analysis. b. IFN-α secretion from
whole or depleted PBMC, or isolated CD14+ cells and pDC, was measured by ELISA 48 h post-CVA21 treatment. c. CM was generated from whole
or depleted PBMC, following treatment with 0.1 pfu/PBMC CVA21 for 48 h. The cytotoxicity of CM against kasumi-1 (i) and HL-60 (ii) cells after 96
h was evaluated by MTS assay. d. NK cell CD69 expression (i) and NK cell CD107a/b degranulation (ii) after treatment of whole of depleted PBMC
with 0.1pfu/cell CVA21 for 48 h was determined. e. ICAM/KG-1 cells (±CVA21 and without addition of mDC) were used to prime CTL and PBMCs
depleted of CD14+ monocytes or pDC were used as effector cells. Tumor-specific CTLs were detected using CD107a/b degranulation assays
against cell targets. Error bars indicate SEM. *denotes statistical significance. n.s. = not significant
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